Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott’s Wallis trial

This article was originally published in The Gray Sheet

Executive Summary

First subject implanted in the U.S. with the firm's Wallis dynamic stabilization spinal implant to treat degenerative disc disease as part of a 340-patient, 20-center clinical trial to support PMA approval. Unlike total disc replacement, such as Johnson & Johnson's Charité, the device does not require an abdominal insertion and does not replace the disc but instead re-routes spinal load through the use of spacers. Abbott acquired Wallis developer Spine Next for $60 mil. in 2004 (1"The Gray Sheet" Nov. 1, 2004, p. 5)...

You may also be interested in...

Nonfusion Alternative To Artificial Discs Acquired By Abbott/Spinal Concepts

Abbott Labs will launch a clinical trial early next year supporting a PMA submission for Spine Next's Wallis nonfusion spine stabilization device, having acquired the French manufacturer for $60 mil. and potential milestone payments

Merz Consumer Care Optimistic About Future As German Lockdown Continues

Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure. 

Towa Plans 10 Launches In December 2020

After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts